retatrutide triple agonist glp-1 gip glucagon receptor Agonism Based Therapies for Obesity Retatrutide Obesity Triple Agonist Targeting

Possible relation to pancreatitis or pancreatic adenocarcinoma Another type of study of the exocrine pancreas has been to give GLP-1 mimetics or DPP-4 inhibitors to animals over a prolonged period of time and evaluate the pancreas for evidence of pancreatitis or precancerous lesions

In addition to their weight loss benefits, these drugs also act through gut-brain signaling and central nervous system pathways involved in appetite, reward, and feeding behavior, although the extent to which individual agents cross the blood-brain barrier remains an active area of investigation

Subcutaneous absorption rates vary somewhat by injection site

The 18 to 24 months between now and retatrutide availability is not wasted time

2022;5(9):e2231982

Treatment requires specialist prescribing, regular monitoring for adverse effects including pancreatitis, and integration with lifestyle modifications